Treatment of fatigue in patients with stable coronary heart disease by sulbuthiaminum

Introduction. Asthenia is an exhausting symptom accompanying coronary heart disease (CHD).
Aim. Assess the effectiveness of asthenic syndrome therapy with sulbutiamin in patients with CHD.
Materials and methods. Asthenia was diagnosed in 2.373 outpatients with chronic non-communicable diseases. Of the 282 participants with stable CHD, asthenia was diagnosed in 131 (mean age 65.3 ± 10.5 years, 74 women and 57 men). Asthenia was indicated using MFI-20 and FSS scales. Patients were divided into three groups: Group 1 – 63 patients without Sulbutiaminum and lifestyle change, Group 2 – 38 patients who changed their lifestyle, Group 3 – 30 patients who changed their lifestyle and received sulbutiamine 600 mg/day for 4 weeks.
Results. The first screening showed the median total score on the FSS scale in the 3rd group was 43.5 points and was significantly higher than in the 1st and 2nd groups (41.0 and 42.0 points). On the MFI-20 scale, the median total score in the 3rd group was 59.5 points and significantly exceeded the indicators of the 2nd group (50.5 points). In dynamics, the 3rd group showed a significant decrease on the MFI-20 scale to 34.0 and a decrease on the FSS scale to normal 28.0 points (р = 0.001). Analysis of the asthenia subtypes in the 3rd group revealed a significant decrease in the indicators of decreased activity to 6.0 points and of mental asthenia to 4.0 points (р = 0.001).
Conclusion. The results show high efficiency of lifestyle modification and Sulbutiaminum treatment in patients with CHD and asthenia.

1. Ralapanawa U, Sivakanesan R. Epidemiology and the Magnitude of Coronary Artery Disease and Acute Coronary Syndrome: A Narrative Review. J Epidemiol Glob Health. 2021;11(2):169–177. https://doi.org/10.2991/jegh.k.201217.001.

2. Sharifzoda KhS. Some risk factors of cardiovascular diseases. Healthcare of Tajikistan. 2019;(2):98–106. (In Russ.) Available at: https://www.zdrav.tj/jour/article/view/128/122.

3. Raizen DM, Mullington J, Anaclet C, Clarke G, Critchley H, Dantzer R et al. Beyond the symptom: the biology of fatigue. Sleep. 2023;46(9):zsad069. https://doi.org/10.1093/sleep/zsad069.

4. Gecaite-Stonciene J, Bunevicius A, Burkauskas J, Brozaitiene J, Neverauskas J, Mickuviene N et al. Validation of the Multidimensional Fatigue Inventory with Coronary Artery Disease Patients. Int J Environ Res Public Health. 2020;17(21):8003. https://doi.org/10.3390/ijerph17218003.

5. Peskovets RD, Shtarik SYu. Association between psychological risk factors and ischaemic heart disease in the open population of a large industrial centre of Eastern Siberia. Siberian Medical Review. 2021;131(5):47–53. (In Russ.) https://doi.org/10.20333/25000136-2021-5-47-53.

6. Shimokhina NYu, Baranovich ZhR, Yunevich AS, Savchenko AA, Zimnickaja OV, Petrova MM. The prevalence of anxiety syndrome in people with chronic non-communicable diseases in real clinical practice. South Russian Journal of Therapeutic Practice. 2023;4(2):101–108. (In Russ.) https://doi.org/10.21886/2712-8156-2023-4-2-101-108.

7. Guan S, Xiaerfuding X, Ning L, Lian Y, Jiang Y, Liu J et al. Effect of job strain on job burnout, mental fatigue and chronic diseases among civil servants in the xinjiang uygur autonomous region of China. Int J Environ Res Public Health. 2017;14(8):872. https://doi.org/10.3390/ijerph14080872.

8. Antonio DAF, Muller AG, Butcher RCGES. Reliability and viability of using the Multidimensional Fatigue Inventory-20 in patients with chronic coronary artery disease. Rev Esc Enferm USP. 2019;53:e03511. https://doi.org/10.1590/S1980-220X2018029203511.

9. Matura LA, Malone S, Jaime-Lara R, Riegel B. A Systematic Review of Biological Mechanisms of Fatigue in Chronic Illness. Biol Res Nurs. 2018;20(4):410–421. https://doi.org/10.1177/1099800418764326.

10. Vaes AW, Goërtz YMJ, van Herck M, Beijers RJHCG, Beers M, Burtin C et al. Physical and mental fatigue in people with non-communicable chronic diseases. Ann Med. 2022;54(1):2522–2534. https://doi.org/10.1080/07853890.2022.2122553.

11. Hulme K, Safari R, Thomas S, Mercer T, White C, Van der Linden M et al. Fatigue interventions in long term, physical health conditions: a scoping review of systematic reviews. PLoS ONE. 2018;13(10):e0203367. https://doi.org/10.1371/journal.pone.0203367.

12. Vink M, Vink-Niese A. Cognitive behavioural therapy for myalgic encephalomyelitis/chronic fatigue syndrome is not effective. Re-analysis of a cochrane review. Health Psychol Open. 2019;6(1):2055102919840614. https://doi.org/10.1177/2055102919840614.

13. Chu SH, Zhao X, Komber A, Cheyne J, Wu S, Cowey E et al. Systematic review: Pharmacological interventions for the treatment of post-stroke fatigue. Int J Stroke. 2023;18(9):1071–1083. https://doi.org/10.1177/17474930231196648.

14. Sevim S, Kaleağası H, Taşdelen B. Sulbutiamine shows promising results in reducing fatigue in patients with multiple sclerosis. Mult Scler Relat Disord. 2017;16:40–43. https://doi.org/10.1016/j.msard.2017.05.010.

15. Gurak SV, Parfenov VA. Asthenia after stroke and myocardial infarction and its treatment with enerion. Clinical Gerontology. 2005;11(8):9–12. (In Russ.) Аvailable at: https://elibrary.ru/hqutcz.

16. 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.) https://doi.org/10.15829/1560-4071-2020-4076.

17. Karpov YuA, Barbarash OL, Boshchenko AA, Kashtalap VV, Kuharchuk VV, Mironov VM et al. Eurasian Guidelines for the diagnostics and management of stable coronary artery disease (2020-2021). Eurasian Heart Journal. 2021;(3):54–93. (In Russ.) https://doi.org/10.38109/2225-1685-2021-3-54-93.

18. Bakalidou D, Krommydas G, Abdimioti T, Theodorou P, Doskas T, Fillopoulos E. The Dimensionality of the Multidimensional Fatigue Inventory (MFI-20) Derived From Healthy Adults and Patient Subpopulations: A Challenge for Clinicians. Cureus. 2022;14(6):e26344. https://doi.org/10.7759/cureus.26344.

19. Machado MO, Kang NC, Tai F, Sambhi RDS, Berk M, Carvalho AF et al. Measuring fatigue: a meta-review. Int J Dermatol. 2021;60(9):1053–1069. https://doi.org/10.1111/ijd.15341.

20. Wu L, Jin H. A systematic review of post-stroke fatigue measurement scale based on COSMIN guidelines. Front Neurol. 2024;15:1411472. https://doi.org/10.3389/fneur.2024.1411472.

21. Gecaite-Stonciene J, Hughes BM, Burkauskas J, Bunevicius A, Kazukauskiene N, van Houtum L et al. Is Associated With Diminished Cardiovascular Response to Anticipatory Stress in Patients With Coronary Artery Disease. Front Physiol. 2021;12:692098. https://doi.org/10.3389/fphys.2021.692098.

22. Ji X, Yu H. Factors Associated with Self-Regulatory Fatigue in Chinese Older Patients with Coronary Heart Disease: A Cross-Sectional Survey. Patient Prefer Adherence. 2023;17:941–949. https://doi.org/10.2147/PPA.S400996.

23. Knoop V, Mathot E, Louter F, Beckwee D, Mikton C, Diaz T et al. Measurement properties of instruments to measure the fatigue domain of vitality capacity in community-dwelling older people: an umbrella review of systematic reviews and meta-analysis. Age Ageing. 2023;52(Suppl 4):iv26–iv43. https://doi.org/10.1093/ageing/afad140.

24. Kazukauskiene N, Bunevicius A, Gecaite-Stonciene J, Burkauskas J. Fatigue, Social Support, and Depression in Individuals With Coronary Artery Disease. Front Psychol. 2021;12:732795. https://doi.org/10.3389/fpsyg.2021.732795.

25. Polikandrioti M, Kalafatakis F, Koutelekos I, Kokoularis D. Fatigue in heart failure outpatients: levels, associated factors, and the impact on quality of life. Arch Med Sci Atheroscler Dis. 2019;4:e103–e112. https://doi.org/10.5114/amsad.2019.85406.

26. Carney RM, Freedland KE, Rich MW. Treating Depression to Improve Survival in Coronary Heart Disease: What Have We Learned? J Am Coll Cardiol. 2024;84(5):482–489. https://doi.org/10.1016/j.jacc.2024.05.038.

27. Hankey GJ, Hackett ML, Almeida OP, Flicker L, Mead GE, Dennis MS et al. Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration. Stroke. 2021;52(8):2502–2509. https://doi.org/10.1161/STROKEAHA.120.033070.

28. Lundström E, Isaksson E, Greilert Norin N, Näsman P, Wester P, Mårtensson B et al. Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke: Results From EFFECTS, a Randomized Controlled Trial. Stroke. 2021;52(10):3082–3087. https://doi.org/10.1161/STROKEAHA.121.034705.

29. Starling-Soares B, Carrera-Bastos P, Bettendorff L. Role of the Synthetic B1 Vitamin Sulbutiamine on Health. J Nutr Metab. 2020;2020:9349063. https://doi.org/10.1155/2020/9349063.